Agenus to Present on Seven Novel Programs at SITC 2020

• Clinical Responses: AGEN1181 (Fc-enhanced anti-CTLA-4) +/- balstilimab
• Clinical Data: Zalifrelimab efficacy in refractory rare tumors
• Clinical & Preclinical Data: AGEN 2373 (anti-CD137)
• Phase 2 Data: Optimizing treatment with balstilimab +/- zalifrelimab
• Cell Therapy with Allogeneic Cells: AgenT-797 (iNKT cells)
• Differentiated TIGIT: Fc enhancement to optimize anti-TIGIT antibody function
• Artificial Intelligence (AI): Predicting responders and new targets with VISION platform

LEXINGTON, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. AGEN, an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that seven abstracts were accepted for presentation at the virtual SITC 2020 Annual Meeting from November 9-14, 2020.

Presentation Details:

Abstract title: AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy (NCT03860272)

Abstract number: 398

Presenting author: Dr. Stephen O'Day

ePoster and audio session times: 11/12 4:50-5:20pm; 11/14 1:00-1:30pm

Abstract title: Single-agent Zalifrelimab (anti-CTLA-4) Shows Clinical Benefit in Rare Tumors - Case Report from Phase 2 Study (NCT03104699)

Abstract number: 245

Presenting author: Dr. Cesar Perez

ePoster and audio session times: 11/11 5:15-5:45pm; 11/13 4:40-5:10pm

Abstract title: AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects

Abstract number: 377

Presenting author: Dr. Claire Galand

ePoster and audio session times: 11/11 5:15-5:45; 11/13 4:40-5:10pm

Abstract title: Pseudoprogression Patterns: Analysis from 2 Independent Phase-2 Studies with Immunotherapy for Recurrent Cervical Cancer

Abstract number: 267

Presenting author: Dr. David O'Malley

ePoster and audio session times: 11/11 5:15-5:45pm; 11/13 4:40-5:10pm

Abstract title: AgenT-797, a novel allogenic and "off-the shelf" iNKT cell therapy promotes effective tumor killing

Abstract number: 164

Presenting author: Dr. Burcu Yigit

ePoster and audio session times: 11/12 4:50-5:20; 11/14 1:00-1:30pm

Abstract title: Anti-TIGIT antibodies require enhanced FcγR co-engagement for optimal T and NK cell-dependent anti-tumor immunity

Abstract number: 253

Presenting author: Rebecca Ward

ePoster and audio session times: 11/11 5:15-5:45pm; 11/13 4:40-5:10pm

Abstract title: Beyond PD-L1: novel PD-1 biomarkers identified by driving T cell dysfunction in vitro

Abstract number: 70

Presenting author: Dr. Simarjot Pabla

ePoster and audio session times: 11/12 4:50-5:20pm; 11/14 1:00-1:30pm

There was a premature disclosure of at least one Agenus abstract on the conference website, which reflected data that was only available at the time of abstract submission in August 2020. Updated data will be presented at the conference and will become available on the Agenus website at https://investor.agenusbio.com/events-and-presentations following the presentations on November 9-14, 2020.

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential of Agenus' product candidates, as well as the anticipated presentation of updated clinical and preclinical data. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contact:

Agenus Inc. 

Caroline Bafundo

212-994-8209

Caroline.bafundo@agenusbio.com